Overview

Methylphenidate and Parkinson's Disease

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine if methylphenidate (MPD), a drug marketed in the U.S. to treat hyperactivity and narcolepsy, added to levodopa, will increase the beneficial effects of levodopa without bothersome side effects in people with Parkinson's disease (PD).
Phase:
Phase 2
Details
Lead Sponsor:
Oregon Health and Science University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)
Treatments:
Methylphenidate